<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192943</url>
  </required_header>
  <id_info>
    <org_study_id>CA017-048</org_study_id>
    <nct_id>NCT03192943</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors</brief_title>
  <official_title>A Phase 1 Study for Safety and Tolerability of BMS-986205 Administered in Combination With Nivolumab (BMS-936558) in Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability for the combination
      therapy of BMS-986205 and Nivolumab in patients with advanced tumors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2017</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>15 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>15 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>15 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Laboratory Abnormalities</measure>
    <time_frame>15 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs leading to discontinuation</measure>
    <time_frame>Up to one year</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the Pharmacokinetics (PK) of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration at the end of the dosing interval (Ctrough)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady-state (Vss/F)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery over 24 hours (%UR24)</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>To characterize the PK of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Availability</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To characterize the immunogenicity of nivolumab when administered in combination with BMS-986205</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To investigate the preliminary anti-tumor activity of BMS-986205 administered in combination with nivolumab in advanced malignant tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to one year</time_frame>
    <description>To investigate the preliminary anti-tumor activity of BMS-986205 administered in combination with nivolumab in advanced malignant tumors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monotherapy and combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986205</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified day</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

          -  Participants must have histologic or cytological confirmation of a malignancy that is
             advanced (metastatic and/or unresectable) with measureable disease per Response
             Evaluation Criteria In Solid Tumors (RECIST v1.1)

          -  Participants must have received, and then progressed or been intolerant to standard
             treatment regimen in the advanced or metastatic setting

          -  Eastern Cooperative Oncology Group performance status of â‰¤ 1

        Exclusion Criteria:

          -  Participants with known or suspected CNS metastases, untreated CNS metastases, or with
             the CNS as the only site of disease are excluded

          -  History of congenital or autoimmune hemolytic disorders

          -  History or presence of hypersensitivity or idiosyncratic reaction to methylene blue

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

